7KM5

Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1

7KM5 の概要

• エントリーDOI: 10.2210/pdb7km5/pdb
• 分子名称: Spike protein S1, nanobody, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
• 機能のキーワード: rbd, nanobody, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2, COVID-19 virus); 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 79089.59

構造登録者

Ye, G.,Shi, K.,Aihara, H.,Li, F. (登録日: 2020-11-02, 公開日: 2021-08-04, 最終更新日: 2024-11-13)

主引用文献

Ye, G.,Gallant, J.,Zheng, J.,Massey, C.,Shi, K.,Tai, W.,Odle, A.,Vickers, M.,Shang, J.,Wan, Y.,Du, L.,Aihara, H.,Perlman, S.,LeBeau, A.,Li, F.
The development of Nanosota - 1 as anti-SARS-CoV-2 nanobody drug candidates.
Elife, 10:-, 2021

PubMed Abstract: Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody), , from a camelid nanobody phage display library. Structural data showed that bound to the oft-hidden receptor-binding domain (RBD) of SARS-CoV-2 spike protein, blocking viral receptor angiotensin-converting enzyme 2 (ACE2). The lead drug candidate possessing an Fc tag () bound to SARS-CoV-2 RBD ~3000 times more tightly than ACE2 did and inhibited SARS-CoV-2 pseudovirus ~160 times more efficiently than ACE2 did. Administered at a single dose, demonstrated preventive and therapeutic efficacy against live SARS-CoV-2 infection in both hamster and mouse models. Unlike conventional antibodies, was produced at high yields in bacteria and had exceptional thermostability. Pharmacokinetic analysis of c documented an excellent in vivo stability and a high tissue bioavailability. As effective and inexpensive drug candidates, may contribute to the battle against COVID-19.

PubMed: 34338634
DOI: 10.7554/eLife.64815

実験手法

X-RAY DIFFRACTION (3.19 Å)